Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

IRVINE, Calif.: IRVINE, Calif., Dec. 15, 2021 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus...

Click to view original post